Health Care·Biotechnology·$24.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.51 | N/A | -6.97% |
management commentary, guidance changes, and full analysis available with Pro.
| -6.97% |
Tone: Defensive
Overall, management expressed concerns about external pressures affecting performance. They are focused on navigating these challenges.
Management highlighted ongoing challenges in the current market environment.
They emphasized the importance of maintaining operational efficiency.
The earnings report indicates that United Therapeutics faced some challenges, leading to a slight miss on EPS. The stock reacted negatively, dropping 13.15%, likely due to investor concerns about the company's ability to manage external pressures. Without guidance, investors may be uncertain about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TELADOC HEALTH INC
Feb 22, 2022